LADDER - Sponsored by Roche/GenenthechCompleted Study | Duration: 38 weeks
LADDER was a multicenter, randomized, active-treatment controlled Phase II clinical trial for the treatment of wet AMD that evaluated the safety and efficacy of the Ranibizumab Port Delivery System (RPDS). RPDS is a surgically implanted intraocular device that delivers the drug Ranibizumab, brand name Lucentis®, to the retina. As opposed to the current method of monthly intravitreal injections for patients with chronic or recurrent wet AMD, RPDS offers a sustained and long-term medication delivery system that decreases the number of eye injections while potentially improving treatment outcome. This study was for patients who had been newly diagnosed with wet AMD within nine months prior to enrollment.